Apoptosis-based therapies and drug targets - PubMed (original) (raw)
Review
. 2005 Aug:12 Suppl 1:942-61.
doi: 10.1038/sj.cdd.4401556.
Affiliations
- PMID: 15665817
- DOI: 10.1038/sj.cdd.4401556
Review
Apoptosis-based therapies and drug targets
U Fischer et al. Cell Death Differ. 2005 Aug.
Abstract
The pathogenesis of many diseases is most closely connected with aberrantly regulated apoptotic cell death. The past 15 years have witnessed an explosion in the basic knowledge of mechanisms that regulate apoptosis and the mediators that either trigger or inhibit cell death. Consequently, great interest has emerged in devising therapeutic strategies for modulating the key molecules of life-and-death decisions. Numerous novel approaches are currently being followed employing gene therapy and antisense strategies, recombinant biologics or classical organic and combinatorial chemistry in order to target specific apoptotic regulators. Although drug development is still in its infancy, several therapeutics have progressed to clinical testing or have even been approved in record time. This review outlines the recent advances in the field of apoptosis-based therapies and explores some highlights of a very active field of drug development.
Similar articles
- From bench to clinic with apoptosis-based therapeutic agents.
Nicholson DW. Nicholson DW. Nature. 2000 Oct 12;407(6805):810-6. doi: 10.1038/35037747. Nature. 2000. PMID: 11048733 Review. - New approaches and therapeutics targeting apoptosis in disease.
Fischer U, Schulze-Osthoff K. Fischer U, et al. Pharmacol Rev. 2005 Jun;57(2):187-215. doi: 10.1124/pr.57.2.6. Pharmacol Rev. 2005. PMID: 15914467 Review. - Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T. Hesry V, et al. Prostate. 2006 Jun 15;66(9):987-95. doi: 10.1002/pros.20421. Prostate. 2006. PMID: 16541419 - Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X, Yue P, Khuri FR, Sun SY. Liu X, et al. Cancer Res. 2005 Oct 15;65(20):9169-75. doi: 10.1158/0008-5472.CAN-05-0939. Cancer Res. 2005. PMID: 16230375
Cited by
- Preclinical studies identify non-apoptotic low-level caspase-3 as therapeutic target in pemphigus vulgaris.
Luyet C, Schulze K, Sayar BS, Howald D, Müller EJ, Galichet A. Luyet C, et al. PLoS One. 2015 Mar 6;10(3):e0119809. doi: 10.1371/journal.pone.0119809. eCollection 2015. PLoS One. 2015. PMID: 25748204 Free PMC article. - Some natural flavonoids are competitive inhibitors of Caspase-1, -3 and -7 despite their cellular toxicity.
White JB, Beckford J, Yadegarynia S, Ngo N, Lialiutska T, d'Alarcao M. White JB, et al. Food Chem. 2012 Apr 15;131(4):1453-1459. doi: 10.1016/j.foodchem.2011.10.026. Food Chem. 2012. PMID: 22140296 Free PMC article. - Selective induction of tumor cell apoptosis by a novel P450-mediated reactive oxygen species (ROS) inducer methyl 3-(4-nitrophenyl) propiolate.
Sun X, Ai M, Wang Y, Shen S, Gu Y, Jin Y, Zhou Z, Long Y, Yu Q. Sun X, et al. J Biol Chem. 2013 Mar 29;288(13):8826-37. doi: 10.1074/jbc.M112.429316. Epub 2013 Feb 4. J Biol Chem. 2013. PMID: 23382387 Free PMC article. - Temporal regulation of apoptotic and anti-apoptotic molecules after middle cerebral artery occlusion followed by reperfusion.
Chelluboina B, Klopfenstein JD, Gujrati M, Rao JS, Veeravalli KK. Chelluboina B, et al. Mol Neurobiol. 2014 Feb;49(1):50-65. doi: 10.1007/s12035-013-8486-7. Epub 2013 Jun 28. Mol Neurobiol. 2014. PMID: 23813097 Free PMC article. Review. - Potential Anticancer Properties and Mechanisms of Action of Formononetin.
Jiang D, Rasul A, Batool R, Sarfraz I, Hussain G, Mateen Tahir M, Qin T, Selamoglu Z, Ali M, Li J, Li X. Jiang D, et al. Biomed Res Int. 2019 Jul 28;2019:5854315. doi: 10.1155/2019/5854315. eCollection 2019. Biomed Res Int. 2019. PMID: 31467899 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous